Anti-Mouse CXCL9 [MIG-2F5-5] In Vivo Antibody - Low Endotoxin
- SKU:
- IVMB0274
- Product Type:
- In Vivo Monoclonal Antibody
- Clone:
- MIG-2F5-5
- Protein:
- CXCR3
- Isotype:
- IgG
- Reactivity:
- Mouse
- Synonyms:
- MIG-1
- Synonyms:
- MIG
- Research Area:
- Immunology
- Endotoxin Level:
- Low Endotoxin
- Host Species:
- Armenian Hamster
- Applications:
- FC
- Applications:
- IF
- Applications:
- In Vivo
- Applications:
- N
Description
Product Name: | Anti-Mouse CXCL9 (Clone MIG-2F5-5) In Vivo Antibody - Low Endotoxin |
Product Code: | IVMB0274 |
Size: | 1 mg, 5 mg, 25 mg, 50 mg, 100 mg |
Clone: | MIG-2F5-5 |
Protein: | CXCR3 |
Product Type: | Monoclonal Antibody |
Synonyms: | MIG-1, MIG |
Isotype: | IgG |
Reactivity: | Mouse |
Applications: | FC, IF, In Vivo, N |
Formulation: | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
Purity: | ≥95% monomer by analytical SEC ⋅ >95% by SDS Page |
Product Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Applications: | FC, IF, In Vivo, N |
Reactivity: | Mouse |
Host Species: | Armenian Hamster |
Specificity: | MIG-2F5-5 activity is directed against murine CXCL9 (monokine induced by gamma interferon, MIG). |
Antigen Distribution: | CXCL9 is mainly secreted by macrophages, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-gamma and is also expressed in intratumoral dendritic cells. |
Immunogen: | Mouse plasmacytoid dendritic cells |
Concentration: | ≥ 5.0 mg/ml |
Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
Formulation: | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Purity: | ≥95% monomer by analytical SEC ⋅ >95% by SDS Page |
Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Storage and Handling: | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles. |
CXCL9 is a chemokine, which are small 8-15 kDa proteins that function in immune responses1. CXCL9, -10, -11 and their receptor CXCR3 regulate immune cell migration, differentiation, and activation, leading to tumor suppression in the paracrine axis. However, in the autocrine axis, they may be involved in tumor growth and metastasis. The CXCL9, -10, -11/CXCR3 axis also regulates differentiation of naïve T cells to T helper 1 (Th1) cells. CXCL9, -10, and -11 are usually expressed at low levels but are upregulated by cytokine stimulation. CXCL9 is dependent on IFNgamma for expression2. CXCL9 is also capable of direct antimicrobial activity against pathogen infection3. CXCL9 is secreted by macrophages4, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-gamma1 and is also expressed in intratumoral dendritic cells5. CXCL9 is also detectable in CD103+ conventional dendritic cells (cDCs) isolated from transgenic murine MMTV-PyMT tumors following in vivo administration of brefeldin A5. Additionally, CXCL9 is detectable in myeloid cells following ex vivo stimulation with IFN-gamma. Furthermore, CXCL9 expression is enhanced in CD8α+ cDC1s when anti-TIM-3 is added. Neutralizing antibodies against Galectin-9 lead to an increase in CXCL9 expression comparable to that induced by anti-TIM-3 antibody. Additionally, endothelial cell expression of CXCL9 is strongly increased in liver sinusoidal endothelial cells isolated from nonalcoholic steatohepatitis mouse livers6. MIG-2F5-5 was generated by immunizing male Armenian hamsters with recombinant murine CXCL9, and specificity was confirmed by ELISA7.